PRISM BioLab (206A) · RiskMaterialised
Variability in Revenue Recognition Due to Delays in R&D Progress
First written in FY2024. 1 of 2 entries say "Materialised", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Uncertainty in License Milestone RevenueA theme 19 companies write about · 19 as a headwind · 1 as a tailwind
PRISM BioLab moved to the "Worse" side of this theme in 2025, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Materialised".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2025MaterialisedAnnual report
「Following the termination of the agreement with Lilly, no remaining performance obligations existed. Accordingly, the entire remaining contract liability was released and recognized as revenue for the fiscal year.」
The contract liability decreased by ¥663.479 million following the termination of the collaboration agreement, and the timing and amount of revenue recognition varied depending on the contractual arrangements. - FY2024First statedAnnual report
「If research and development is delayed or the R&D policy of the licensing partner changes, this may affect our operating results and financial position.」
A revenue structure in which upfront payments, milestones and royalties depend on the development stage and the licensing partner's policy.